RTTNews) - Gilead Sciences Inc. (GILD) announced that phase 1 study data showed two different formulations of once-yearly lenacapavir, administered via intramuscular injection, achieved and maintained plasma concentrations exceeding those associated with HIV prevention efficacy...
GET PAID FOR SHOPPING AT ALL YOUR FAVORITE STORES!
Sound too good to be true? Here’s the deal: Stores pay us a commission for sending you their way.
We share that with you as Cash Back. Everyone wins! SIGN UP FOR FREE!
.png)
COOL ROOM ENTERTAINMENT 10530 Campus Way South #1174 Largo, MD 20774
(916) 619-1308
teosmoot@gmail.com
Copyright © 2024 Cool Room Entertainment. All Rights Reserved
